While circulating markers such as complement fragments and interleukins have shown promise as indicators of disease activity in mouse models of AMD, few studies have quantitatively assessed their incremental predictive value beyond established genetic (e.g., CFH, ARMS2) or imaging biomarkers. Here, ARMS2 is linked to age-related macular degeneration.